Related Experiment Video
Updated: Dec 30, 2025
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Predicting Therapeutic Antibody Delivery into Human Head and Neck Cancers
Guolan Lu1, Shayan Fakurnejad2, Brock A Martin3
1Department of Otolaryngology - Head and Neck Surgery, Stanford University School of Medicine, Stanford, California.
Purpose:
The efficacy of antibody-based therapeutics depends on successful drug delivery into solid tumors; therefore, there is a clinical need to measure intratumoral antibody distribution. This study aims to develop and validate an imaging and computation platform to directly quantify and predict antibody delivery into human head and neck cancers in a clinical study.
Experimental Design:
Twenty-four patients received systemic infusion of a near-infrared fluorescence-labeled therapeutic antibody followed by surgical tumor resection. A computational platform was developed to quantify the extent of heterogeneity of intratumoral antibody distribution. Both univariate and multivariate regression analyses were used to select the most predictive tumor biological factors for antibody delivery. Quantitative image features from the pretreatment MRI were extracted and correlated with fluorescence imaging of antibody delivery.
Results:
This study not only confirmed heterogeneous intratumoral antibody distribution in-line with many preclinical reports, but also quantified the extent of interpatient, intertumor, and intratumor heterogeneity of antibody delivery. This study demonstrated the strong predictive value of tumor size for intratumoral antibody accumulation and its significant impact on antibody distribution in both primary tumor and lymph node metastasis. Furthermore, this study established the feasibility of using contrast-enhanced MRI to predict antibody delivery.
Conclusions:
This study provides a clinically translatable platform to measure antibody delivery into solid tumors and yields valuable insight into clinically relevant antibody tumor penetration, with implications in the selection of patients amenable to antibody therapy and the design of more effective dosing strategies.
Insights
This study developed a novel imaging and computation platform to measure antibody delivery in head and neck cancers. Tumor size and MRI scans effectively predict antibody distribution, aiding therapeutic strategies.
Area of Science:
- Oncology
- Pharmacology
- Medical Imaging
Background:
- Antibody therapeutics require effective delivery into solid tumors for efficacy.
- Measuring intratumoral antibody distribution is crucial for optimizing cancer treatment.
- Current methods lack direct quantification of antibody penetration in clinical settings.
Purpose of the Study:
- To develop and validate an imaging and computation platform for quantifying antibody delivery into human head and neck cancers.
- To predict intratumoral antibody distribution using clinical data and imaging.
- To assess the heterogeneity of antibody delivery in solid tumors.
Main Methods:
- Systemic infusion of near-infrared fluorescence-labeled antibodies in 24 patients undergoing tumor resection.
- Development of a computational platform to quantify intratumoral antibody distribution heterogeneity.
- Analysis of pre-treatment MRI features and correlation with antibody delivery using regression models.
Main Results:
- Confirmed heterogeneous intratumoral antibody distribution across patients and tumors.
- Demonstrated tumor size as a significant predictor of antibody accumulation and distribution.
- Established the feasibility of using contrast-enhanced MRI to predict antibody delivery into tumors.
Conclusions:
- A clinically translatable platform for measuring antibody delivery into solid tumors was established.
- Insights into antibody tumor penetration can guide patient selection for antibody therapy.
- Findings support the design of optimized dosing strategies for antibody-based treatments.
